Download inmunologia y genetica aplicada (ingenasa), s

INMUNOLOGIA Y GENETICA APLICADA (INGENASA), S.A.
Development of diagnosis methods based on monoclonal antibodies,
recombinant proteins and molecular diagnostic
Contact person details
Name:
RUEDA , Paloma ( Dr)
Name of
Organisation:
INMUNOLOGIA Y GENETICA APLICADA (INGENASA), S.A.
URL:
http://www.ingenasa.es
E-mail:
Contact
Telephone:
+34-91-3680501
Fax number:
+34-91-4087598
Collaboration
Type: Company Expertise
Title: Development of diagnosis methods based on monoclonal antibodies,
recombinant proteins and molecular diagnostic
Participation: Type A
Type Details: INGENASA is engaged in several research projects contracted with
clients interested in our know-how and technologies. Our present focus is in the
following areas:
-Development of diagnostics and vaccines against animal viruses
-Gene expression technology
-Monoclonal antibodies development
-Epitope mapping
-Molecular diagnosis (PCR, RFLPs, real-time PCR)
From the point of view of biological products the development of new technologies:
recombinant DNA and Molecular Biology have allowed a great advance in the
production of safer vaccines, free of residual infectivity.
INGENASA has studied in great detail the molecular characteristics of the
Parvoviruses, a family of viruses of great economical relevance in Animal Health.
Consequently, INGENASA has developed a new method which allows the
reconstruction of empty viral particles, nucleic acid-free. This method is based on the
use of the baculovirus expression system. The VP2 genes of porcine and canine
parvovirus were cloned into this system and expressed in insect cells. The resulting
protein shows the ability to self-assemble into particles which were structurally and
antigenically indistinguishable from the PPV or CPV virions. The final result is the
production of a new generation of highly immunogenic and very safe vaccines. An
spin-off of this research has been the use of these VLPs as an antigen delivery
system to stimulate both humoral and cellular immune responses, included CTL
responses.
These new technologies of empty viral particles can be applied to other viruses and
opens the possibility of developing polyvalent vaccines combining antigens from
different viruses and other sources. This technology has been filed for patent
protection.
More recently the use of IBDV-derived assemblies VLPs mainly VP2 icosahedral
capsids has been proved as a suitable candidate recombinant vaccine.
Programme: FP6-LIFESCIHEALTH , FP7-HEALTH
Instruments: COLLECTIVE SMEs-Collective research projects,COOPERATIVE SMEsCo-operative research contracts,IP Integrated Project,NoE Networks of
Excellence,STIP Specific Targeted Innovation Project,STREP Specific Targeted
Research Project,CP-FP Small or medium-scale focused research project,CP-IP
Large-scale integrating project,CP-TP Collaborative Project targeted to a special
group (such as SMEs)
Research interest: Immunology, serology, transplantation, Veterinary medicine,
Microbiology, bacteriology, virology, mycology, Nucleic acids, protein synthesis,
Diagnostics
Expiry Date: 2008-11-22
Workprogramme area(s)/key action(s):
(FP6-LIFESCIHEALTH LSH-2005-1.2.2-4) Development of new diagnostics
(FP6-LIFESCIHEALTH LSH-2005-1.2.3-4) Development of new in vitro tests to
replace animal experimentation
(FP6-LIFESCIHEALTH LSH-2005-1.2.4-2) Hepatitis C vaccine
(FP6-LIFESCIHEALTH LSH-2005-1.2.4-6) Use of baculovirus as a vector in gene
therapy (especially orientated towards small and medium sized companies)
(FP6-LIFESCIHEALTH LSH-2005-1.2.4-7) Development and testing of new preventive
and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell
therapies, for example those on neurological and neuromuscular disorders) and
immunotherapies
(FP6-LIFESCIHEALTH LSH-2005-2.1.2-4) Development of new diagnostic tests for
the management and control of antimicrobial resistance
(FP6-LIFESCIHEALTH LSH-2005-2.2.0-7) Innovative technological approaches for
cancer therapy
(FP7-HEALTH HEALTH-1.1) High-throughput research
(FP7-HEALTH HEALTH-1) Biotechnology, generic tools and medical technologies for
human health
(FP7-HEALTH HEALTH-2007-1.2) Detection, diagnosis and monitoring
Target Partner
Expertise:
Country:
World
Organization Details
Name:
INMUNOLOGIA Y GENETICA APLICADA (INGENASA), S.A.
Department:
Address:
Madrid
ESPAÑA
Type:
SME (Small or Medium sized Enterprise)
Number of
Employees:
10 - 49
Details:
Keywords:
Enzyme immunoassays (ELISA)
Monoclonal antibodies
Baculovirus expression system
Protein expression
Virus-like particles
Vaccines
Assembly
Delivery system
Partners already
acquired